Table 2.
Clinical Characteristics of the Patients with Essential Hypertension Treated with Calcium Channel Blockers, ARBs, ACEIs, β-blockers, and Diuretics
| Variable | Calcium channel blockers (n=261) |
ARBs (n=201) |
ACEIs (n=52) |
β -blockers (n=58) |
Diuretics (n=79) |
|---|---|---|---|---|---|
| Body mass index (kg/m2) | 23.9 ± 2.7 | 23.8 ± 3.1 | 23.7 ± 3.0 | 23.8 ± 2.8 | 23.4 ± 2.9 |
| Systolic blood pressure (mm Hg) | 140.5 ± 14.1 | 143.2 ± 13.8 | 144.1 ± 13.9 | 142.3 ± 13.5 | 144.3 ± 12.8 |
| Diastolic blood pressure (mm Hg) | 82.3 ± 10.7 | 84.5 ± 10.5 | 84.7 ± 11.4 | 83.9 ± 9.8 | 85.2 ± 11.2 |
| Heart rate (bpm) | 71.2 ± 10.1 | 69.7 ± 8.9 | 68.6 ± 9.3 | 66.2 ± 8.2 | 70.2 ± 9.6 |
| Total cholesterol (mmol/L) | 4.98 ± 0.63 | 4.79 ± 0.65 | 4.78 ± 0.72 | 5.01 ± 0.74 | 5.09 ± 0.79 |
| Triglycerides (mmol/L) | 1.14 ± 0.43 | 1.09 ± 0.45 | 1.13 ± 0.52 | 1.15 ± 0.49 | 1.21 ± 0.55 |
| HDL cholesterol (mmol/L) | 1.46 ± 0.33 | 1.39 ± 0.32 | 1.39 ± 0.32 | 1.42 ± 0.35 | 1.49 ± 0.42 |
| LDL cholesterol (mmol/L) | 3.29 ± 0.67 | 3.17 ± 0.59 | 3.34 ± 0.69 | 3.39 ± 0.58 | 3.48 ± 0.87 |
| Glucose (mmol/L) | 5.0 ± 0.2 | 4.9 ± 0.3 | 4.8 ± 0.3 | 4.9 ± 0.2 | 5.0 ± 0.4 |
| Insulin (pmol/L) | 42.1 ± 9.8 | 43.2 ± 11.3 | 44.3 ± 13.9 | 40.4 ± 12.7 | 39.9 ± 14.1 |
| Creatinine (μmol/L) | 88.1 ± 17.2 | 84.2 ± 13.9 | 82.3 ± 14.5 | 89.5 ± 18.3 | 91.2 ± 18.7 |
| Sodium (mmol/L) | 140.3 ± 1.1 | 141.0 ± 1.5 | 140.9 ± 1.4 | 140.1 ± 1.4 | 140.0 ± 1.6 |
| Potassium (mmol/L) | 4.1 ± 0.1 | 4.2 ± 0.3 | 4.2 ± 0.2 | 4.2 ± 0.2 | 4.0 ± 0.1 |
| Statin treatment (%) | 15 | 18 | 17 | 14 | 18 |
| Smoker (%) | 27 | 29 | 31 | 30 | 27 |
ARBs indicates angiotensin type I receptor blockers; ACEIs, angiotensin-converting enzyme inhibitor; HDL, high density lipoprotein; LDL, low density lipoprotein.
Without statistical significant differences for the rest parameters